John Dallas1, Lee Skrupky2, Nurelign Abebe3, Walter A Boyle4, Marin H Kollef5. 1. Department of Pulmonary and Critical Care Medicine, Barnes-Jewish Hospital, St. Louis, MO. 2. Department of Pharmacy, Barnes-Jewish Hospital, St. Louis, MO. 3. Department of Internal Medicine, St. Luke's Hospital, St. Louis, MO. 4. Department of Anesthesiology and Surgery, Washington University School of Medicine, Barnes-Jewish Hospital, St. Louis, MO. 5. Department of Pulmonary and Critical Care Medicine, Barnes-Jewish Hospital, St. Louis, MO. Electronic address: mkollef@dom.wustl.edu.
Abstract
BACKGROUND: Ventilator-associated tracheobronchitis (VAT) is considered an intermediate condition between bacterial airway colonization and ventilator-associated pneumonia (VAP). The purpose of this prospective cohort study was to further characterize VAT in terms of incidence, etiology, and impact on patient outcomes. METHODS: Patients intubated for >48 h in the surgical and medical ICUs of Barnes-Jewish Hospital were screened daily for the development of VAT and VAP over 1 year. Patients were followed until hospital discharge or death, and patient demographics, causative pathogens, and clinical outcomes were recorded. RESULTS: A total of 28 patients with VAT and 83 with VAP were identified corresponding to frequencies of 1.4% and 4.0%, respectively. VAP was more common in surgical than medical ICU patients (5.3% vs 2.3%; P<.001), but the occurrence of VAT was similar between surgical and medical patients (1.3% vs 1.5%; P=.845). VAT progressed to VAP in nine patients (32.1%) despite antibiotic therapy. There was no significant difference in hospital mortality between patients with VAP and VAT (19.3% vs 21.4%; P=.789). VAT was caused by a multidrug-resistant (MDR) pathogen in nine cases (32.1%). CONCLUSION: VAT occurs less commonly than VAP but at a similar incidence in medical and surgical ICU patients. VAT frequently progressed to VAP, and patients diagnosed with VAT had similar outcomes to those diagnosed with VAP, suggesting that antimicrobial therapy is appropriate for VAT. VAT is also frequently caused by MDR organisms, and this should be taken into account when choosing antimicrobial therapy.
BACKGROUND: Ventilator-associated tracheobronchitis (VAT) is considered an intermediate condition between bacterial airway colonization and ventilator-associated pneumonia (VAP). The purpose of this prospective cohort study was to further characterize VAT in terms of incidence, etiology, and impact on patient outcomes. METHODS:Patients intubated for >48 h in the surgical and medical ICUs of Barnes-Jewish Hospital were screened daily for the development of VAT and VAP over 1 year. Patients were followed until hospital discharge or death, and patient demographics, causative pathogens, and clinical outcomes were recorded. RESULTS: A total of 28 patients with VAT and 83 with VAP were identified corresponding to frequencies of 1.4% and 4.0%, respectively. VAP was more common in surgical than medical ICU patients (5.3% vs 2.3%; P<.001), but the occurrence of VAT was similar between surgical and medical patients (1.3% vs 1.5%; P=.845). VAT progressed to VAP in nine patients (32.1%) despite antibiotic therapy. There was no significant difference in hospital mortality between patients with VAP and VAT (19.3% vs 21.4%; P=.789). VAT was caused by a multidrug-resistant (MDR) pathogen in nine cases (32.1%). CONCLUSION: VAT occurs less commonly than VAP but at a similar incidence in medical and surgical ICU patients. VAT frequently progressed to VAP, and patients diagnosed with VAT had similar outcomes to those diagnosed with VAP, suggesting that antimicrobial therapy is appropriate for VAT. VAT is also frequently caused by MDR organisms, and this should be taken into account when choosing antimicrobial therapy.
Authors: Andre C Kalil; Mark L Metersky; Michael Klompas; John Muscedere; Daniel A Sweeney; Lucy B Palmer; Lena M Napolitano; Naomi P O'Grady; John G Bartlett; Jordi Carratalà; Ali A El Solh; Santiago Ewig; Paul D Fey; Thomas M File; Marcos I Restrepo; Jason A Roberts; Grant W Waterer; Peggy Cruse; Shandra L Knight; Jan L Brozek Journal: Clin Infect Dis Date: 2016-07-14 Impact factor: 9.079
Authors: Jennifer A Muszynski; James Sartori; Lisa Steele; Randall Frost; Wei Wang; Nadeem Khan; Anthony Lee; Ada Lin; Mark W Hall; Onsy Ayad Journal: Pediatr Crit Care Med Date: 2013-06 Impact factor: 3.624
Authors: Pranita D Tamma; Alison E Turnbull; Aaron M Milstone; Christoph U Lehmann; Emily R M Sydnor; Sara E Cosgrove Journal: Clin Infect Dis Date: 2011-05-02 Impact factor: 9.079
Authors: Catia Cillóniz; Santiago Ewig; Miquel Ferrer; Eva Polverino; Albert Gabarrús; Jorge Puig de la Bellacasa; Josep Mensa; Antoni Torres Journal: Crit Care Date: 2011-09-14 Impact factor: 9.097